VEGFA and colorectal carcinoma: Interestingly, bevacizumab, an anti-VEGF mAb, was shown to have a survival benefit when used in combination with standard therapy for the treatment of CRC in patients with known dMMR (HR 0.52, 95% CI = 0.29–0.94, p = 0.02) [51].